A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
Cheng Ean CheeMelissa OoiSoo-Chin LeeRaghav SundarValerie HeongWei-Peng YongChin Hin NgAndrea WongJoline S J LimDavid S P TanRoss SooJoshua T C TanSong YangMin ThuraAbdul Qader Al-AidaroosWee Joo ChngQi ZengBoon-Cher GohPublished in: Targeted oncology (2023)
PRL3-zumab, a first-in-class humanized antibody, was safe and tolerable in solid tumors and hematological malignancies.